iBio highlights NHP data showing IBIO-610 may preserve muscle with GLP-1 therapy

iBio, Inc. filed an 8-K on October 13, 2026 disclosing preclinical body-composition data from an obese non-human primate study of IBIO-610, described as potentially a first-in-class Activin E antibody candidate, tested alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity.¹ The data were presented orally at the European Association for the Study of Diabetes Annual Meeting on October 1, 2026.¹

In the eight-week study, lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone.¹ A further breakdown of the same study, which enrolled six animals per group, found that at week 8, fat accounted for 93% of the weight lost by NHPs given a single dose of IBIO-610 alongside twice-weekly semaglutide, compared with 77% for NHPs given semaglutide alone.¹

These findings add to earlier results from the same study, where IBIO-610 demonstrated a 97% reduction in serum levels of active Activin E at week 8 following a single intravenous dose.¹ The company also reported that IBIO-610 had a 33.2-day half-life in NHPs, with a projected human half-life potentially supporting twice-yearly dosing.¹

iBio's chief executive, Martin Brenner, said in the release that in this NHP study, IBIO-610 delivered durable, near-complete inhibition of active Activin E, and when combined with semaglutide, nearly all observed weight loss came from fat.¹

The company stated it plans to begin first-in-human studies in the first half of 2027.¹ iBio cautioned in its forward-looking statements that findings in NHPs may not be replicated in humans, and that its ability to start first-in-human trials in the first half of 2027 is subject to risks of product development and regulatory approval.¹